文献速递鼻科

生物制剂治疗2型弥漫性/嗜酸性慢性鼻窦炎手术患者的持续疾病预测因素

Predictors of persistent disease in biologic treated type 2 diffuse/eosinophilic chronic rhinosinusitis undergoing surgery.
PubMed 文献 · Int Forum Allergy Rhinol · 2023-10-08

横断面研究纳入37例因哮喘接受生物制剂治疗的慢性鼻窦炎伴鼻息肉(CRSwNP)患者,均在生物制剂治疗期间行内镜鼻窦手术。术后6个月评估显示,疾病控制不佳者组织嗜酸性粒细胞减少、血清中性粒细胞增高;组织嗜酸性粒细胞减少可预测疾病控制不佳(OR=0.21,95%CI [0.05, 0.83],p=0.03)。血清中性粒细胞≥5.75×10^9细胞/L可预测需补救全身糖皮质激素。

要点

  • 生物制剂治疗期间组织嗜酸性粒细胞减少与CRSwNP控制不佳相关(OR=0.21,95%CI [0.05, 0.83],p=0.03)。
  • 疾病控制不佳者组织嗜酸性粒细胞>100个/高倍视野比例8.3% vs 50.0%(p<0.001)。
  • 血清中性粒细胞≥5.75×10^9细胞/L预测需补救全身糖皮质激素(敏感度80.0%,特异度96.9%,AUC=0.938,p=0.002)。

核心结论

  • 生物制剂治疗期间低组织嗜酸性粒细胞和血清中性粒细胞增高可预测CRSwNP对生物制剂治疗反应不佳。
  • 血清中性粒细胞水平≥5.75×10^9细胞/L预测当前生物制剂治疗反应不佳。

研究设计与样本

  • 横断面研究,纳入37例因哮喘接受生物制剂治疗并在生物制剂治疗期间行内镜鼻窦手术的CRSwNP患者(年龄47.8±12.4岁,女性43.2%)。
  • 术后6个月评估时,将生物制剂治疗期间CRSwNP控制不佳者与控制者比较,采用手术时(6个月前)的血和黏膜样本预测疾病控制。

主要发现

  • 疾病控制不佳者组织嗜酸性粒细胞>100个/高倍视野比例8.3% vs 控制者50.0%(p<0.001),血清中性粒细胞5.2±2.7 vs 3.7±1.1×10^9细胞/L(p=0.02)。
  • 逻辑回归分析显示组织嗜酸性粒细胞减少预测疾病控制不佳(OR=0.21,95%CI [0.05, 0.83],p=0.03)。
  • 受试者工作特征分析显示,血清中性粒细胞截断值5.75×10^9细胞/L预测需补救全身糖皮质激素(敏感度80.0%,特异度96.9%,AUC=0.938,p=0.002)。

关键数值与推荐

  • 组织嗜酸性粒细胞减少预测疾病控制不佳的OR=0.21(95%CI [0.05, 0.83],p=0.03)。
  • 血清中性粒细胞截断值5.75×10^9细胞/L预测需补救全身糖皮质激素:敏感度80.0%,特异度96.9%,AUC=0.938,p=0.002。
  • 疾病控制不佳者组织嗜酸性粒细胞>100个/高倍视野比例8.3% vs 控制者50.0%(p<0.001)。
  • 疾病控制不佳者血清中性粒细胞5.2±2.7 vs 控制者3.7±1.1×10^9细胞/L(p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologic therapy targeting type 2 chronic rhinosinusitis with nasal polyps (CRSwNP) has greatly improved disease control but nonresponders exist in a proportion of patients in phase 3 trials and clinical practice. This study explores the serum and histologic changes in biologic treated CRSwNP that predict disease control. METHODS: A cross-sectional study was performed of patients with CRSwNP on biologics for their asthma, who underwent endoscopic sinus surgery while on biologic therapy. At the 6-month postoperative assessment, patients with poorly controlled CRSwNP while on biologic therapy were compared to patients who were controlled. Blood and mucosal samples taken at the time of surgery 6 months prior were assessed to predict disease control. RESULTS: A total of 37 patients were included (age 47.8 ± 12.4 years, 43.2% female). Those with poorly controlled disease had reduced tissue eosinophils (% >100 cells/high-powered field: 8.3% vs. 50.0%, p < 0.001) and increased serum neutrophils (5.2 ± 2.7 vs. 3.7 ± 1.1 × 109 cells/L, p = 0.02). Logistic regression analysis demonstrated that reduced tissue eosinophil was predictive for poorly controlled disease (OR = 0.21, 95% CI [0.05, 0.83], p = 0.03). Receiver-operating characteristic analysis showed that need for rescue systemic corticosteroid was predicted at a serum neutrophil cut-off level of 5.75 × 109 cells/L (sensitivity = 80.0%, specificity = 96.9%, AUC = 0.938, p = 0.002). CONCLUSION: Low tissue eosinophils and increased serum neutrophils while on biologics predict for poor response in the biological treatment of with CRSwNP. A serum neutrophil level of ≥5.75 × 109 cells/L predicts for poor response to current biologic therapy.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Png LH, Kalish L, Campbell RG, et al. Predictors of persistent disease in biologic treated type 2 diffuse/eosinophilic chronic rhinosinusitis undergoing surgery. Int Forum Allergy Rhinol. 2023. PMID: 37805956. doi:10.1002/alr.23282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。